Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merrion Pharmaceuticals, LLC
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Prostate Cancer with rising PSA levels after hormone treatment and bone metastasis based on an X-ray.
You may not be if
Already be on a bisphosphonate treatment (Zometa, Fosamax, Actonel)
Clareo Health | Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
